ANAPTYSBIO, INC. (ANAB) Total liabilities 2017–2026
ANAPTYSBIO, INC. (ANAB) total liabilities at each fiscal year-end, per SEC filings.
$327.2MFY2026 · since FY2017: $100.4M → $327.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | $327.2M | -20.8% |
| FY2025 | $413.0M | +13.4% |
| FY2024 | $364.3M | +4.6% |
| FY2023 | $348.3M | +21.5% |
| FY2022 | $286.6M | +1346.2% |
| FY2021 | $19.8M | -34.3% |
| FY2020 | $30.2M | +33.4% |
| FY2019 | $22.6M | +3.9% |
| FY2018 | $21.8M | -78.3% |
| FY2017 | $100.4M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More ANAB financial trends
ANAB RevenueANAB Net incomeANAB Net marginANAB Gross profitANAB Gross marginANAB Operating incomeANAB Operating marginANAB Operating cash flowANAB Free cash flowANAB Capital expendituresANAB Return on equityANAB Stock buybacksANAB Dividends paidANAB Total assetsANAB Shareholders’ equityANAB overview →